

AD-A043 905

SCRIPPS CLINIC AND RESEARCH FOUNDATION LA JOLLA CA DI--ETC F/G 6/5  
PREVENTION OF HEMOGLOBINURIC NEPHROSIS.(U)  
APR 77 P V SACKS

DADA17-73-C-3041  
NL


UNCLASSIFIED

| OF |  
AD  
A043905



END  
DATE  
FILMED

9 -77  
DDC



MICROCOPY RESOLUTION TEST CHART  
NATIONAL BUREAU OF STANDARDS-1963-A

AD A 043905

(12)

AD \_\_\_\_\_

(6)

PREVENTION OF HEMOGLOBINURIC NEPHROSIS.

(9)

1 Final Scientific Report.  
February 1973-31 May 1975,

(10)

Peter V. Sacks, M.D.  
Scripps Clinic and Research Foundation  
La Jolla, California

(11) April 1977

(12) 6p.

(15) DADA 17-73-C-3041

Supported by



U. S. Army Medical Research and Development Command  
Washington, D. C. 20314

-17-

Contract No. DADA-73-C-3041

AD No. \_\_\_\_\_  
DDC FILE COPY

DDC AVAILABILITY STATEMENT - A

Approved for public release; distribution unlimited

1473  
4 10 373

1B

REPORT DOCUMENTATION PAGE		READ INSTRUCTIONS BEFORE COMPLETING FORM
1. REPORT NUMBER	2. GOVT ACCESSION NO.	3. RECIPIENT'S CATALOG NUMBER
4. TITLE (and Subtitle)  PREVENTION OF HEMOGLOBINURIC NEPHROSIS		5. TYPE OF REPORT & PERIOD COVERED Final Scientific Report 2/1/73 to 5/31/75
		6. PERFORMING ORG. REPORT NUMBER
7. AUTHOR(s)  Peter V. Sacks, M.D.		8. CONTRACT OR GRANT NUMBER(s)  DADA-73-C-3041 <i>new</i>
9. PERFORMING ORGANIZATION NAME AND ADDRESS Division of Hematology-Oncology <i>New</i> Scripps Clinic and Research Foundation 10666 N. Torrey Pines Road La Jolla, CA 92037		10. PROGRAM ELEMENT, PROJECT, TASK AREA & WORK UNIT NUMBERS
11. CONTROLLING OFFICE NAME AND ADDRESS Scripps Clinic and Research Foundation 10666 N. Torrey Pines Road La Jolla, CA 92037		12. REPORT DATE April 1977
		13. NUMBER OF PAGES 3
14. MONITORING AGENCY NAME & ADDRESS (if different from Controlling Office)		15. SECURITY CLASS. (of this report)
		15a. DECLASSIFICATION/DOWNGRADING SCHEDULE
16. DISTRIBUTION STATEMENT (of this Report) 4 copies HQDA 12 copies Defense Documentation Center 1 copy Superintendent, Academy of Health Sciences, US Army 1 copy Dean, School of Medicine, Uniformed Services University of the Health Sciences		
17. DISTRIBUTION STATEMENT (of the abstract entered in Block 20, if different from Report)  Same as above		
18. SUPPLEMENTARY NOTES		
19. KEY WORDS (Continue on reverse side if necessary and identify by block number) Hemoglobinuria Hemoglobinuric nephrosis Plasma hemoglobin Paroxysmal nocturnal hemoglobinuria		
20. ABSTRACT (Continue on reverse side if necessary and identify by block number)  L → Intravenous injection into rabbits, baboons and humans of large volumes of hemoglobin (in frozen-thawed blood) caused hemoglobinuria without any evidence of renal disturbance, nor was there evidence of clinically significant disseminated intravascular coagulopathy (DIC). The rate of urinary hemoglobin excretion was determined. In the baboon, the simultaneous injection of dextran solution did not modify the rate of <i>(contin p1473B)</i>		

20. (Abstract continued *A* p 1473 A)

hemoglobin excretion. In one patient with nocturnal hemoglobinuria, infusion of dextran solution was associated with decreased hemoglobin excretion.

ACCESSION for	
NTIS	White Section <input checked="" type="checkbox"/>
DDC	Buff Section <input type="checkbox"/>
UNANNOUNCED	<input type="checkbox"/>
JUSTIFICATION	
BY	
DISTRIBUTION/AVAILABILITY CODES	
Dr	SPECIAL
<i>A</i>	

1473 B



Contract Number: DADA-73-C-3041

PREVENTION OF HEMOGLOBINURIC NEPHROSIS - Peter V. Sacks, M.D.

FINAL SCIENTIFIC REPORT

1973-1974

Human studies on the efficacy of dextran infusions for the prevention of experimentally induced hemoglobinuria were deferred upon instruction from the Army Investigational Drug Review Board pending the outcome of preliminary experiments on two animal species.

Rabbit experiments were performed first, to standardize procedures and methods. We found no evidence of DIC (disseminated intravascular coagulation). The dextran had no effect on tests for DIC, or on the clearance of plasma hemoglobin. The urinary sediment showed no abnormality.

In baboons, coagulation studies showed a moderate, although significant, fall in platelet count with prolongation of the partial thromboplastin time following the infusion of autologous hemolyzed whole blood, and shortening of the thrombin time after dextran infusion. Fibrin split products developed in 4 of 5 experiments after hemolysate injection, with the suggestion of a facilitated response when dextran was infused prior to the hemolysate. We concluded from these studies that the induction of acute experimental hemoglobinemia in baboons using autologous hemolyzed whole blood resulted in the development of mild DIC, and that a preliminary infusion of 70,000 Mw dextran may facilitate the development, or impede the clearance, of fibrin split products. None of these changes approached levels of clinical significance so that the response, when it occurred, could be classified as mild, subclinical, DIC.

Prior to the granting of the contract we undertook standardization of the experimental model in human subjects. Autologous, stroma-containing, hemoglobin solutions were prepared by freezing and thawing whole blood and the resulting lysates were infused into ourselves and other human volunteers. In other experiments hemoglobinuria was induced by the rapid injection of small volumes of distilled water. None of these procedures induced untoward symptoms. Replicate testing after induction of hemoglobinemia-hemoglobinuria in human subjects demonstrated no evidence of DIC. Urinary sediments remained normal throughout. We concluded from this, and from the work of others who have done similar experiments in humans, that the induction of hemoglobinuria with autologous hemolyzed red cells produces no DIC, renal damage or unpleasant side-effects.

We performed in vitro experiments with dextran and hemoglobin using column chromatography, cellulose-acetate electrophoresis and membrane ultrafiltration, but were unable to demonstrate complex formation between the two molecules.

1974-1975

On instruction from the Army Investigational Drug Review Board, experiments designed to examine the effects of 6% Dextran-70 on induced hemoglobinemia and hemoglobinuria in normal human subjects were again deferred. The Board was concerned by the proposal to use autologous stroma-containing hemoglobin solutions (whole blood lysates) in these studies. A subsequent opinion of the Board (reported to us verbally by Maj. B. Brient on 30 May 74 indicated that the use of autologous stroma-free hemoglobin solutions to induce hemoglobinuria would be permitted. The study protocol was redesigned to use autologous, stroma-free hemoglobin solutions to induce hemoglobinuria. Because the production of such stroma-free hemoglobin solutions requires considerable processing, it was questioned whether such solutions should be classified as a "drug" therapy requiring permission from the AIDRB for use as an 'Investigational New Drug'--even though these autologous solutions were to be used to gather experimental data and not for therapeutic evaluation. We await a ruling by the AIDRB on this point and have been obliged to defer these studies.

A single patient with paroxysmal nocturnal hemoglobinuria (PNH) was given 6% Dextran-70 in saline on two separate occasions during phases of active hemoglobinuria. Simultaneous measurements of plasma hemoglobin levels and urine hemoglobin output (mg/min) were made before, during and after the infusion of dextran. Dextran was rapidly effective in halting hemoglobinuria on both occasions. It is not clear whether this effect is mediated at the level of reducing intravascular hemolysis of PNH cells or through an effect on the renal clearance of plasma hemoglobin. Further patients with active PNH need to be studied to establish dextran's mode of action. Such patients are difficult to come by.

Pending clarification of the status of our studies on induced hemoglobinuria in normal human subjects, we initiated further experiments in rabbits in an attempt to develop a satisfactory animal model for chronic intravascular hemolysis. We showed that adaptation of ultrasound and wire wool-containing prostheses to extracorporeal arterio-venous shunts in rabbits did not provide satisfactory models for this purpose.

### Publications

1. Spector, J.I., Wilson, C.B., and Crosby, W.H.: Coagulation studies and correlative histology during experimental hemoglobinemia in rabbits. Am. J. Path. 74:567, 1974.
2. Spector, J.I. and Crosby, W.H.: Coagulation studies during experimental hemoglobinemia in humans. J. Appl. Physiol. 38:195, 1975.
3. Spector, J.I., Lang, J.E. and Crosby, W.H.: Coagulation changes in baboons during acute experimental hemoglobinemia and dextran infusion. Am. J. Path. 78:469, 1975.



DISTRIBUTION LIST

4 copies	HQDA (SGRD-RP) WASH DC 20314
12 copies	Defense Documentation Center (DDC) ATTN: DDC-TCA Cameron Station Alexandria, Virginia 22314
1 copy	Superintendent Academy of Health Sciences, US Army ATTN: AHS-COM Fort Sam Houston, Texas 78234
1 copy	Dean School of Medicine Uniformed Services University of the Health Sciences Office of the Secretary of Defense 6917 Arlington Road Bethesda, MD 20014